Gujarat Kidney And Super Speciality Limited has informed the Exchange regarding Outcome of Board Meeting held on March 19, 2026.
GKSL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The board of Gujarat Kidney and Super Speciality Limited met on March 19, 2026, and approved two appointments: Mr. Dharmendra Bhaliya (Practicing Company Secretary) as Secretarial Auditor and Mr. Siddharth Atulbhai Shah (Chartered Accountant) as Internal Auditor, both for FY 2025-26. The board also ratified and resubmitted actions from its February 14, 2026 meeting with minor typographical corrections. The filing includes the company's unaudited standalone and consolidated financial results for Q2 and H1 FY2025-26 (quarter and half year ended September 30, 2025), along with the limited review report from statutory auditor Y. M. Shah & Co. Standalone H1 FY26 revenue from operations stood at ₹2,109.25 lakhs with a profit after tax of ₹620.10 lakhs, compared to ₹1,867.05 lakhs and ₹563.13 lakhs in the previous year's corresponding period.
This is a routine governance and compliance update — auditor appointments are standard annual requirements and do not signal any material change. The resubmission of H1 results suggests administrative correction rather than any restatement of substance. Shareholders should note the results reflect steady revenue and profit growth year-on-year, but the announcement itself is unlikely to move the stock.